In the article “Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment”,1 which appeared in Volume 94, Issue 45 of Medicine, funding information was originally omitted. The article has since been corrected online.
REFERENCE
- 1.Werner RA, Schmid JS, Muegge DO, et al. Prognostic value of serum tumor markers in medullary thyroid cancer patients undergoing vandetanib treatment. Medicine 2015. 94:e2016. [DOI] [PMC free article] [PubMed] [Google Scholar]